Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-05-27
Item 8.01
National Fuel Gas Company disclosed the exercise of optional redemption rights for $300 million in 5.50% Notes due October 2026, with a redemption date of June 11, 2026. While this is a material debt management action affecting the company's capital structure and liquidity, it does not fit cleanly into the specific event categories (not a covenant breach, not a going-concern issue, not a restatement). The redemption is a routine but material corporate finance event that a reasonable investor would want to know about.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
Item 8.01
Hoth Therapeutics, Inc. changed its corporate name to Rocket One Inc. and its ticker symbol from HOTH to RKTO, effective May 27, 2026. The company also formed and renamed a wholly-owned subsidiary from Rocket One Inc. to Rocket One.0 Inc. as part of the corporate restructuring.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 5.03
The Board unanimously adopted Second Amended and Restated Bylaws on May 25, 2026, removing a provision that previously allowed unauthorized or defective transactions to be cured through Board or stockholder approval, materially affecting stockholder derivative suit protections and corporate liability exposure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
This disclosure reports the consummation of an IPO generating $75 million in gross proceeds and a concurrent private placement of $3 million, with trust account establishment. While IPO completion is material to investors, the filing does not fit cleanly into the standard taxonomy categories—it is neither a traditional earnings release, M&A activity, nor a dilutive issuance (which typically refers to unregistered secondary offerings). The event is material but best classified as other_material given the specialized nature of SPAC IPO completion and trust account mechanics.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 5.03
The filing discloses an amendment to the Certificate of Designation increasing authorized Series B Cumulative Convertible Preferred Stock from 397,222 to 572,222 shares (a 44% increase). While this is a structural/governance change disclosed under Item 5.03, the material substance is an expansion of convertible preferred equity capacity, which could signal dilution risk or capital-raising activity. This does not fit neatly into the more specific categories (it is not a dilutive issuance itself, nor a routine bylaw amendment), so other_material is most appropriate.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 5.03
The filing discloses stockholder approval of an Amended and Restated Certificate of Incorporation that effects board declassification and eliminates supermajority voting requirements, along with corresponding bylaw amendments. While Item 5.03 covers amendments to articles and bylaws, these governance changes are material to investors as they fundamentally alter board composition mechanics and voting thresholds, affecting shareholder rights and corporate control dynamics. This does not fit neatly into the more specific event categories (e.g., it is not an executive appointment, departure, or compensation matter), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 2.03
This disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While Item 2.03 typically captures covenant breaches or material debt arrangements, this filing describes routine debt issuance activity that is material to the Bank's operations but does not fit cleanly into the covenant_breach category (no breach or default is disclosed). The Bank explicitly states "consolidated obligations issuance is material to the Bank," and Schedule A details committed issuances, making this a material event that warrants disclosure but falls outside the more specific event-type categories.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 2.03
This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes totaling approximately $560 million across five separate issuances with varying maturities (2026–2034) and coupon rates (3.83%–5.08%). While Item 2.03 typically signals covenant_breach or debt acceleration events, this filing describes routine debt issuance by a Federal Home Loan Bank in the ordinary course of business—a material financing activity that does not fit the specific covenant_breach taxonomy (which implies a triggering default or acceleration). The disclosure is material to investors assessing the registrant's capital structure and funding activities, but the event itself is a standard debt offering rather than a breach or distress signal.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligation bonds totaling approximately $390 million across three debt securities (trade dates 5/20–5/22/2026, maturing 2027–12/2027). While the filing explicitly states "consolidated obligations issuance is material to the Bank," the event does not fit cleanly into the standard taxonomy: it is neither a covenant breach (no default triggered), nor a dilutive equity issuance, nor a restatement or going-concern disclosure. The creation of direct financial obligations through routine debt issuance by a Federal Home Loan Bank is material to investors but represents ordinary course funding activity rather than an extraordinary event, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-27
Item 8.01
Tonix Pharmaceuticals announced publication of a peer-reviewed Phase 1 clinical trial manuscript for TNX-1500 in the Journal of Clinical Immunology, demonstrating positive immunosuppressive efficacy in blocking T cell-dependent antibody responses at all tested doses. This clinical development milestone is material to investors assessing the company's pipeline progress and de-risking of the lead drug candidate.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-27
bioAffinity Technologies disclosed receipt of a patent allowance notification from the Mexican Institute of Industrial Property for a method related to lung cancer prediction using flow cytometry. While this is a positive intellectual property development, it does not fit cleanly into the standard 8-K event taxonomy (not earnings, M&A, executive changes, impairments, litigation, or cybersecurity). Patent allowances can be material to biotech/diagnostic companies' competitive positioning and valuation, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-27
Item 8.01
NextNav announced an election to redeem all outstanding public warrants at $0.01 per warrant with a June 26, 2026 redemption date. This material capital structure event affects warrant holders' rights and the company's equity structure, disclosed via press release and other events notice.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
Murphy USA disclosed the issuance of $500 million in 5.875% Senior Notes due 2034 under Item 8.01 (Other Events). While this is a material debt financing event that would affect investor assessment of the company's capital structure and financial obligations, it does not fit cleanly into the more specific event categories (e.g., it is not a restatement, covenant breach, or going-concern disclosure). The issuance of material debt is a significant corporate event, but the 8-K taxonomy lacks a dedicated "debt_issuance" category, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-27
Item 8.01
Precision Biosciences disclosed late-breaking clinical data from its Phase 1 ELIMINATE-B trial presented at EASL Congress 2026, including new biopsy data demonstrating cccDNA elimination in PBGENE-HBV, establishment of pgRNA as a biomarker, and updated safety profile information. The data directly impacts investor assessment of the company's lead therapeutic candidate and pipeline viability.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 1.01
The Company entered into Extension No. 7 to a convertible promissory note with GHS Investments LLC on May 21, 2026, extending the maturity date from April 29, 2026 to October 31, 2026 and waiving all prior Events of Default. While this is disclosed under Item 1.01 (Material Definitive Agreement), it is fundamentally a debt extension and waiver of defaults rather than entry into a new material acquisition, disposition, merger, or change of control. The repeated extensions and waiver of defaults suggest financial stress, making this material to investors, but it does not fit cleanly into the ma_activity category which contemplates M&A transactions.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 7.01
The Board declared a cash dividend of $0.14 per share on Class I Common Stock, payable June 26, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 8.01
The Company disclosed its net asset value per share of $18.39 for Class I Common Stock as of April 30, 2026 and aggregate NAV of $1.7 billion as of May 26, 2026, along with a status update on its continuous private offering of unregistered shares totaling $2.5 billion in cumulative consideration.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 7.01
Biohaven disclosed new clinical data in epilepsy with opakalim and positive clinical biomarker/patient data via press releases and an R&D Day presentation on May 26-27, 2026. While clinical trial results can be material to investors evaluating pipeline progress and commercial prospects, this disclosure does not fit the standard taxonomy categories (not an earnings release, not a formal restatement, not an impairment). The material nature of clinical data warrants classification as other_material rather than a routine disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-27
Item 7.01
The disclosure announces investor conference participation and reaffirms 2026 non-GAAP earnings guidance of $3.68–$3.83 per diluted share. While guidance reaffirmation is material to investors, it does not fit cleanly into the standard taxonomy (not a new earnings release, not a guidance miss or material change). The Item 7.01 Regulation FD disclosure is primarily administrative notification of conference attendance, but the guidance reaffirmation elevates materiality.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-05-26
Item 1.01
NL Industries completed a reincorporation merger on May 26, 2026, changing its state of incorporation from New Jersey to Delaware through a merger of the Predecessor Corporation into its wholly-owned subsidiary NLI Holdings, Inc. The merger involved automatic 1:1 stock conversion and adoption of new Delaware Certificate of Incorporation and Bylaws, with no change in business operations, management, facilities, assets, liabilities, or net worth. Existing directors and officers automatically transitioned to the new entity on identical terms, and stockholder rights were materially modified through changes in governing law, though the company elected not to be governed by Delaware's anti-takeover provisions under Section 203.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
PNC completed a public offering of $1.65 billion in senior notes ($1.35 billion fixed/floating rate and $300 million floating rate, both due October 2029). While debt issuances are material financing events affecting the registrant's capital structure and liquidity, this disclosure does not fit neatly into the standard 8-K taxonomy—it is neither a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, nor dilutive equity issuance. The Item 8.01 classification and the nature of the transaction (completed debt offering under an existing registration statement) suggest this is a material financing event best captured as "other_material."
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 8.01
Florida Power & Light sold $255.4 million in floating-rate debt securities on May 26, 2026. While this is a material financing event affecting the company's capital structure and future interest obligations, it does not fit cleanly into the standard 8-K taxonomy. The sale is not a dilutive equity issuance (dilutive_issuance applies to equity), not an M&A transaction (ma_activity), and not a covenant breach or going-concern disclosure. As a significant debt issuance by a utility, it is material to investors but lacks a dedicated event category.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 8.01
Following the Annual Meeting, John F. Glick was reappointed as Chair of the Board, and three Board committees were reconstituted. These governance actions affect board structure and oversight responsibilities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
UGI announced early tender results for a $175 million cash tender offer of its 2028 Notes, with $224.8 million tendered (45.6% of outstanding notes) as of the early deadline and pro-rata acceptance at 77.9%, representing material debt management activity affecting the company's capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
The Board of Directors approved a three-for-two stock split, which is a material capital structure change affecting all shareholders' ownership percentages and share count. While stock splits are routine corporate actions, they are material to investors as they affect share price, trading liquidity, and ownership calculations. This does not fit the dilutive_issuance category (which concerns new equity issuance) but represents a significant corporate action disclosed under Item 8.01.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 1.01
Aspira entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation for biomedical research and development, with a $125,000 partnering fee over five years. While this is a material definitive agreement disclosed under Item 1.01, it does not constitute a traditional M&A transaction (no acquisition, merger, or change of control), and the collaboration arrangement with fixed fees and research focus does not fit the more specific event categories. The agreement is material to investors as it represents a significant strategic partnership and commitment of capital.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
Editas disclosed positive preclinical data for EDIT-401 demonstrating robust reductions in LDL-C, Lp(a), and ApoB in non-human primates, along with plans to initiate a first-in-human clinical trial in 2026 and FDA pre-IND feedback. This announcement represents material progress on a lead pipeline candidate for a gene-editing biotech company where clinical advancement is a key value driver.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
The FDA has granted Outlook's appeal of a Complete Response Letter for its BLA for LYTENAVA™, concluding that substantial evidence of effectiveness has been established and directing the company to work on final labeling for resubmission in June 2026. This is a material regulatory milestone for a biopharmaceutical company's lead product candidate, but it does not fit neatly into the standard taxonomy categories (not an earnings release, not a departure/appointment, not M&A, not a restatement or going-concern issue). The favorable FDA determination materially advances the product toward approval and would significantly affect investor assessment of the company's prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Editas suspended and terminated its prospectus supplement for an at-the-market (ATM) offering program with TD Cowen, effectively halting its ability to raise capital through this mechanism without filing a new prospectus. The company had previously raised $43.9 million through this program. While this is a material event affecting the company's financing flexibility, it does not fit neatly into the standard taxonomy—it is neither a dilutive issuance (which describes the sale itself) nor a delisting risk, but rather a suspension of an existing capital-raising program that would materially impact investor assessment of the company's liquidity and financing options.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
This disclosure reports interim clinical and biomarker data from a Phase 1b extension study of GT-02287 for Parkinson's disease, including safety, tolerability, and efficacy endpoints (GluSph reduction of 81%, stable MDS-UPDRS scores, and perceived clinical benefits). While this is a material clinical development update that would affect investor assessment of the drug candidate's progress, it does not fit neatly into the predefined taxonomy—it is neither an earnings release, M&A activity, executive change, nor a negative event like restatement or going concern. The disclosure is material because clinical trial progress is central to a biopharmaceutical company's value proposition.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 8.01
The filing discloses the net asset value (NAV) per share of Eagle Point Trinity Senior Secured Lending Company as of April 30, 2026 ($10.18). For a closed-end investment company or BDC, NAV disclosure is a standard periodic reporting requirement that would be material to investors assessing the fund's performance and valuation, though it does not fit neatly into the more specific event categories (earnings release, impairment, going concern, etc.). This is classified as other_material because it is a substantive disclosure affecting investor assessment but lacks a dedicated taxonomy category.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 7.01
Insulet disclosed a voluntary medical device correction affecting approximately 7 million Omnipod® Pods due to manufacturing issues (cannula tears), with expected costs up to $50 million in 2026. While the company states it does not anticipate disruption to shipments or guidance changes, the scale of the correction (7 million units), the financial impact ($50 million), and the reputational/regulatory implications of a second related correction within months constitute a material event. This does not fit neatly into existing categories (not a restatement, impairment, or litigation settlement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
Silexion announced a 1-for-10 reverse share split effective May 28, 2026, following shareholder approval on May 5, 2026. While reverse splits are routine capital structure adjustments, this disclosure is material because it affects the total mix of information available to investors regarding share ownership, voting power, and trading mechanics. The event does not fit the more specific categories (not a dilutive issuance, not a restatement, not an impairment), making "other_material" the appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 8.01
The Company reported its Net Asset Value as of April 30, 2026 of $9.3 billion total ($24.66 per share across all classes) and fund leverage of 0.8x, providing material valuation and financial position metrics to investors.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
The Board approved a $50 million increase to the share repurchase program, bringing the total authorization to $150 million, reflecting management's confidence in the company's financial position.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Olema announced entry into a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 (Olema's KAT6 inhibitor) in combination with NUBEQA® (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer. This strategic partnership represents a material development for Olema's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 68%
filed 2026-05-26
Item 7.01
Strategy Inc disclosed capital structure updates via press release and maintained a dashboard of capital structure information under Regulation FD Disclosure, though the specific nature of the updates is not detailed in the filing excerpt provided.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Strategy Inc updated investors on its material holdings and liquidity position, disclosing approximately 843,738 bitcoin valued at ~$63.87 billion and a USD Reserve of $871 million designated for dividend and debt service obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 2.03
Graphic Packaging entered into a $141.4 million loan agreement with MEDC to finance tax-exempt green bonds due 2064, creating a direct financial obligation under Item 2.03. While this is a material financing event affecting the company's capital structure and debt profile, it does not fit cleanly into the more specific event categories (e.g., it is not a covenant breach, dilutive issuance, or M&A activity). The green bond financing is material to investors as it represents a significant long-term debt obligation, but the disclosure is primarily a financing arrangement rather than a triggering event like a breach or impairment.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 7.01
ASP Isotopes disclosed a press release and investor presentation regarding the Company's production of Silicon-28, a specialized isotope product. While the disclosure is made under Item 7.01 (Regulation FD Disclosure) and explicitly disclaimed as not "filed" under Section 18, the announcement of a significant production achievement for a specialized isotope company could be material to investors assessing the company's operational progress and commercial viability. However, the filing does not provide specific details about production volumes, commercial significance, or financial impact, making it difficult to classify into a more specific event category; thus "other_material" is most appropriate.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
PBF Energy announced a $500 million private offering of senior unsecured notes due 2034, with proceeds intended to redeem $801.6 million of 2028 Notes, representing a material refinancing of the company's debt structure.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-26
Item 8.01
Corbus Pharmaceuticals disclosed updated Phase 1/2 clinical data for CRB-701 (SYS6002), a Nectin-4 targeted ADC, demonstrating robust activity in oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer, with results to be presented at ASCO 2026 and FDA alignment on registrational trial designs.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 2.03
This disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While Item 2.03 is the appropriate disclosure vehicle for debt issuances, the filing does not fit cleanly into the "covenant_breach" category (which signals financial distress) or other specific event types. The FHLBank explicitly states that "consolidated obligations issuance is material to the FHLBank," and Schedule A details committed debt issuances. This is a material debt financing event that warrants disclosure but lacks a more precise taxonomy match.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Alaunos announced an integrated preclinical readout for ALN1003, its investigational obesity candidate, disclosing results from non-GLP mouse studies. While this is a material development for a clinical-stage biotech company (affecting investor assessment of pipeline progress), it does not fit neatly into the standard taxonomy—it is neither an earnings release (financial results), nor a clinical trial result (no dedicated 8-K Item), nor a material impairment or litigation event. The disclosure is material because preclinical efficacy data for a lead candidate directly informs investor valuation and risk assessment, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 7.01
The filing discloses delivery of a proxy statement for an annual stockholders meeting scheduled for August 7, 2026. While proxy statements are routine corporate governance documents, the disclosure itself under Item 7.01 (Regulation FD Disclosure) does not fit cleanly into the shareholder_vote_results category, which applies to actual voting outcomes post-meeting. This is a pre-meeting disclosure of the proxy materials, which is material to shareholders but lacks a more specific event type in the taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 85%
filed 2026-05-26
Item 8.01
Verra Mobility terminated its contract with Avis Budget Group, a major customer representing over 10% of total revenue in Q1 2026 and FY 2025, and revised full-year 2026 guidance downward as a result of this significant loss of revenue.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
Exzeo announced authorization of a $12 million share repurchase program with a Rule 10b5-1 trading plan effective immediately. While share buybacks are routine capital allocation decisions, the $12 million authorization and formal adoption of a Rule 10b5-1 plan represent a material corporate action that signals management's confidence in valuation and capital deployment strategy. This does not fit neatly into the more specific event categories (not M&A, not compensation, not a departure/appointment), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-26
Item 1.01
BlackRock Monticello Debt REIT entered into a First Amendment to its revolving credit agreement with JPMorgan Chase Bank on May 21, 2026, extending the maturity date to May 20, 2027 and modifying the applicable margin. This refinancing activity materially affects the Company's liquidity and debt obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-26
Item 8.01
The Company disclosed material portfolio and financial metrics as of April 30, 2026, including NAV per Class I share of $24.16, aggregate NAV of approximately $1.1 billion, portfolio fair value of $1.8 billion, $763.8 million in debt outstanding, 88 portfolio companies, and a weighted average yield of 9.8%, along with a monthly distribution declaration of $0.1812 per Class I share.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-26
Item 8.01
The filing discloses that exclusivity provisions in a non-binding letter of intent with Terra Quantum have expired, allowing MLAC II to pursue discussions with other potential business combination targets. While this is a development in M&A discussions, it does not constitute entry into, completion of, or termination of a material acquisition or change of control—the letter of intent was non-binding and exclusivity has merely lapsed. The event is material to investors as it affects the likelihood and scope of a potential business combination, but does not fit cleanly into the ma_activity category, which typically covers binding agreements or completed transactions.
View raw filing on EDGAR →